Evolva secures additional funding for future growth Search jobs Evolva Holding SA / Key word(s): Miscellaneous 17-May-2021 / 07:01 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 KR The issuer is solely responsible for the content of this announcement. Reinach, May 17, 2021 - Evolva (SIX:EVE), the Swiss biotech company focused on the research, development and commercialization of products based on nature, today signed an agreement with Nice & Green, a Swiss investment firm, to secure additional funding. The major activities to be funded include the expansion and diversification of manufacturing capacities in the contract manufacturer network as well as investments into commercial activities to sustain high growth in Health Ingredients and to build the Health Protection business. For these purposes, the investment facility may be drawn in tranches depending on Evolva's operational needs.